For decades, heart failure with preserved ejection fraction has been one of cardiology's most frustrating puzzles. The heart pumps with seemingly normal force, yet patients are breathless climbing stairs, swollen with fluid, and cycling through hospitalizations that chip away at both quality of life and survival. Worse, while treatments for heart failure with reduced ejection fraction have multiplied over the past 30 years, the preserved-ejection-fraction variant, known as HFpEF, has remained stubbornly resistant to almost everything clinicians have thrown at it.
That changed in late 2024, when the SUMMIT trial delivered data that sent a ripple through the cardiology community. Tirzepatide, a dual-receptor agonist originally developed for type 2 diabetes and weight management, achieved a 38% reduction in the combined risk of cardiovascular death or worsening heart failure in patients with obesity-related HFpEF. SUMMIT represents the strongest evidence yet that targeting the metabolic roots of heart failure, not just its hemodynamic symptoms, can meaningfully change outcomes. This post unpacks the SUMMIT trial in depth: what it tested, what it found, why the mechanistic data matter as much as the headline numbers, and what the results mean for the millions of patients living at the intersection of obesity, heart failure, and kidney disease. One must understand the methodology, design, and principal outcomes of recent clinical trials and studies, such as those presented at major cardiovascular conferences, that examine the effects of tirzepatide in heart failure populations.
Why Obesity-Related HFpEF Has Resisted Treatment for So Long
HFpEF now accounts for more than half of all heart failure cases. Approximately 6.7 million American adults live with heart failure, and that number is projected to swell to 11.4 million by 2050. The preserved-ejection-fraction subtype is driving much of that growth, fueled by the parallel rise in obesity, diabetes, and metabolic syndrome across aging populations worldwide.
The obesity connection defines an entire clinical phenotype. Obese patients with HFpEF exhibit a distinct pathophysiology compared to their lean counterparts: greater biventricular dilation, expanded plasma volume, higher resting and exercise filling pressures, and increased epicardial adipose tissue surrounding the heart. Up to 84% of patients in large-scale HFpEF studies are overweight or obese, making the metabolic phenotype the dominant form of the disease in clinical practice
So why have therapies failed? Most interventions targeted downstream consequences, like hemodynamics, neurohormonal activation, and fluid overload, rather than the upstream metabolic machinery driving the disease. Diuretics relieve congestion but don't alter the disease trajectory. SGLT2 inhibitors have shown benefit in reducing hospitalizations, but their effect on the obesity-driven inflammatory cascade is modest. Minerocorticoid receptor antagonists like finerenone show promise but carry kidney-related trade-offs. Until recently, no therapy squarely addressed the triad of excess visceral fat, systemic inflammation, and circulatory volume expansion that defines obese HFpEF. The potential advantages of tirzepatide for individuals with obesity and related conditions, such as kidney disease and heart failure, emphasize its role in populations with significant unmet medical needs.
What Tirzepatide Is and Why Dual-Receptor Agonism Matters
Tirzepatide is a once-weekly injectable peptide that simultaneously activates two incretin receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual mechanism distinguishes it from single-receptor GLP-1 agonists and produces a unique pharmacological profile.
The GLP-1 pathway is already well-established in metabolic medicine. It promotes insulin secretion, suppresses glucagon, slows gastric emptying, and acts on brain appetite centers to reduce food intake. GIP receptor activation, however, adds a layer that researchers are still unpacking. GIP receptors are widely expressed in the ventricular myocardium, and preclinical evidence suggests that GIP signaling may regulate myocardial triglyceride metabolism, inhibit pathological cardiac remodeling, and modulate inflammatory pathways through β-arrestin-dependent mechanisms distinct from classic G protein signaling.
Inside the SUMMIT Trial: How It Was Designed and Who It Enrolled
The SUMMIT trial (A Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity) was an international, double-blind, randomized, placebo-controlled phase 3 trial conducted at 129 centers across nine countries. It enrolled 731 patients between April 2021 and June 2023, with a median follow-up of 104 weeks, nearly two full years.
To enter the study, patients needed all of the following: a clinical diagnosis of heart failure, a left ventricular ejection fraction of 50% or higher, a body mass index of at least 30 kg/m², and documented functional limitations on both the Kansas City Cardiomyopathy Questionnaire (KCCQ) and six-minute walk distance. Roughly half of the participants had been hospitalized or visited urgent care for worsening heart failure in the prior 12 months. This was not a population with mild symptoms. These were patients with established disease and meaningful impairment.
Patients were randomized 1:1 to receive subcutaneous tirzepatide (escalated from 2.5 mg weekly up to 15 mg by week 20) or a matching placebo, stratified by baseline BMI, recent decompensation history, and diabetes status.
The trial tracked two co-primary endpoints: a time-to-first-event composite of adjudicated cardiovascular death or worsening heart failure, and the change in KCCQ Clinical Summary Score (KCCQ-CSS) from baseline to 52 weeks. The KCCQ-CSS is a validated, patient-reported measure that captures symptom burden, physical limitations, and overall quality of life on a 0-to-100 scale — a tool increasingly recognized as one of the most meaningful outcome measures in heart failure research.
The Headline Numbers: A 38% Reduction in a Population Starved for Options
The primary composite endpoint, cardiovascular death or worsening heart failure, occurred in 9.9% of the tirzepatide group compared to 15.3% in the placebo group, yielding a hazard ratio of 0.62 (95% CI, 0.41–0.95; P = 0.026). That 38% relative risk reduction was driven overwhelmingly by fewer worsening heart failure events: 8.0% vs. 14.2% (HR 0.54), representing a 46% reduction in the events that send HFpEF patients back to the hospital.
The quality-of-life data were equally striking. At 52 weeks, patients on tirzepatide improved their KCCQ-CSS by 19.5 points, compared to 12.7 in the placebo group. In heart failure research, a 5-point improvement on the KCCQ is considered clinically meaningful. The tirzepatide group exceeded that threshold by a wide margin, and the improvement reflects what patients feel in daily life: less breathlessness, greater independence, and fewer restrictions on activity. The secondary endpoints reinforced the pattern across multiple domains:
- Six-minute walk distance improved by 26.0 meters with tirzepatide vs. 10.1 meters with placebo (P < 0.001), reflecting real gains in functional capacity.
- Body weight decreased by 13.9% with tirzepatide vs. 2.2% with placebo (P < 0.001), consistent with the drug's known metabolic effects.
- Systolic blood pressure dropped by 4.6 mmHg with tirzepatide vs. a 0.1 mmHg increase with placebo.
- High-sensitivity C-reactive protein (hsCRP) fell by 38.8% with tirzepatide vs. 5.9% with placebo (P < 0.001), signaling a potent anti-inflammatory effect.
- EQ-5D-5L health state index — a general quality-of-life measure — improved by 0.12 with tirzepatide vs. 0.06 with placebo (P < 0.001).
- Composite of all-cause death or worsening heart failure occurred in 11.8% of the tirzepatide group vs. 16.9% of the placebo group (HR 0.67, 95% CI 0.46–0.99).
Ongoing cardiovascular outcomes trials will provide more definitive data on tirzepatide's effect on cardiovascular mortality.
The CKD Connection: ACC.25's Most Clinically Significant Subanalysis
At the American College of Cardiology's 2025 meeting in Chicago, Dr. Milton Packer presented a post-hoc analysis of SUMMIT that zeroed in on a population of patients cardiologists see every day but rarely have good options for: those with the triad of obesity, HFpEF, and chronic kidney disease (CKD). This analysis represents one of the most consequential additions to the original trial data.
Sixty percent of SUMMIT participants had CKD at baseline. Patients with CKD had substantially worse heart failure across every metric: lower KCCQ scores, shorter walk distances, higher NT-proBNP and troponin T levels, and a twofold increase in the risk of worsening heart failure events compared to participants without kidney disease.
The critical finding was that CKD did not blunt tirzepatide's effectiveness. The relative risk reduction for the primary composite endpoint was similar across baseline kidney function groups. In fact, because CKD patients faced higher absolute event rates, the absolute risk reduction was numerically greater in this subgroup, 3.6 fewer events per 100 patients with CKD, compared to 1.6 fewer per 100 without CKD. In practical terms, the patients who need help most appeared to benefit most.
Perhaps equally important, long-term tirzepatide improved kidney function. At 52 weeks, the estimated glomerular filtration rate (eGFR) increased with tirzepatide when measured by both creatinine-based and cystatin C-based methods. The investigators noted some discordance between these two measurement approaches. A complexity is introduced by the fact that weight loss and changes in body composition can independently alter creatinine and cystatin C production. But the directional signal was clear: tirzepatide did not harm the kidneys and likely provided a protective effect.
As Dr. Packer stated at ACC.25, this triad of obesity, HFpEF, and CKD affects an estimated 2 to 3 million U.S. adults who have few effective treatment options. SUMMIT is the first randomized trial to demonstrate meaningful benefit in this population with an incretin-based therapy.
What Clinicians and Patients Should Know About Safety and Practical Considerations
Tirzepatide's safety profile in SUMMIT was consistent with that observed in its diabetes and obesity programs. Gastrointestinal side effects were the most common adverse events and the main reason for treatment discontinuation. Patients and clinicians evaluating tirzepatide for obesity-related HFpEF should weigh several practical factors:
- The dose escalation schedule matters. SUMMIT titrated tirzepatide from 2.5 mg up to 15 mg weekly over approximately 20 weeks. Slower titration may help manage gastrointestinal tolerability, especially in patients with existing GI conditions or those new to incretin-based therapies.
- Weight loss is substantial and sustained. The 13.9% mean weight loss at 52 weeks is clinically significant, but patients and providers should plan for the nutritional and body composition implications of that degree of weight change, particularly in older adults, where sarcopenia is a concern.
- Kidney function should be monitored carefully. While SUMMIT showed renal benefit overall, the early dip in creatinine-based eGFR at 12 weeks requires awareness. Cystatin C-based measurements may provide a more accurate picture in patients undergoing rapid changes in body composition.
- SGLT2 inhibitor co-administration data are limited. Only about 17% of SUMMIT participants were on an SGLT2 inhibitor at baseline. How tirzepatide performs alongside dapagliflozin or empagliflozin in combination remains an important clinical question.
- The trial did not include patients with a BMI below 30. Many HFpEF patients are overweight (BMI 25–29.9) without meeting obesity thresholds. Whether tirzepatide benefits this group is unknown and cannot be extrapolated from SUMMIT.
- Current regulatory status. Tirzepatide is FDA-approved for type 2 diabetes and for chronic weight management in adults with obesity. It does not yet carry a heart failure indication. Any use for HFpEF would currently be off-label, though the SUMMIT data may influence future regulatory decisions and guideline updates.
- Access and cost remain real barriers. Supply constraints and insurance coverage challenges have affected many patients seeking incretin-based therapies. Physician-guided telehealth platforms like Harbor have emerged to help patients navigate access to tirzepatide under medical supervision, though availability and pricing continue to evolve across the market.
- Gastrointestinal side effects don't appear to worsen with kidney disease. The CKD subanalysis showed similar rates of GI symptoms across baseline renal function groups, which is reassuring for the large proportion of HFpEF patients who also have CKD.
Patients interested in exploring whether tirzepatide is appropriate for their situation can start with a quick eligibility assessment to connect with a licensed provider.
What SUMMIT Tells Us About the Future of Heart Failure Medicine
We have learned the viewpoints of heart failure specialists regarding the adoption of tirzepatide as a treatment option, as well as the challenges and potential impact on future heart failure management strategies. Heart failure specialists widely view tirzepatide as a breakthrough for obesity-related HFpEF, with many calling the SUMMIT trial “practice-changing.” Questions remain about optimal patient selection, integration with existing therapies, and durability of benefit. Tirzepatide is poised to reshape heart failure management, but real-world implementation and further research will determine its ultimate impact.
The SUMMIT trial does more than add tirzepatide to the HFpEF treatment algorithm. It validates a broader conceptual shift that has been building for years: the recognition that obesity-driven metabolic disease is not merely a risk factor for heart failure, but a treatable cause of it.
Several developments will shape how this evidence translates into clinical practice over the next few years. The ongoing SURPASS-CVOT trial is evaluating tirzepatide's cardiovascular outcomes in patients with type 2 diabetes, which will provide additional data on cardiovascular death specifically. Guideline committees from the ACC, AHA, and the Heart Failure Society of America will need to decide how to position incretin-based therapies within updated HFpEF treatment algorithms. And the question of combination therapy will likely require dedicated trials.
For the first time, there is robust randomized evidence that a therapy targeting the metabolic roots of the disease can reduce heart failure events, improve functional capacity, reverse adverse cardiac remodeling, and protect kidney function. The SUMMIT trial is not the final word on tirzepatide and heart failure. The interaction with existing standard-of-care therapies needs exploration. But as a proof of concept, SUMMIT represents one of the most important shifts in heart failure medicine in a generation.